MTND2P28: A Potential Drug Target and Biomarker (G100652939)

Target Name: MTND2P28

NCBI ID: G100652939

MTND2P28

Other Name(s): MT-ND2 pseudogene 28

MTND2P28: A Potential Drug Target and Biomarker

Mitochondrial neurodegeneration is a progressive neurodegenerative disorder that is characterized by the progressive loss of brain cells, including neurons and synapses, and the disruption of normal brain function. The symptoms of MTND2P28 include progressive muscle weakness and wasting, cognitive decline, and progressive neurodestruction.

MTND2P28 is a protein that is expressed in the brain and is involved in the development and progression of MTND. The protein is composed of two subunits, alpha- and beta-subunits, and is expressed in the brain, heart, and muscle.

The alpha-subunit of MTND2P28 is a key regulator of mitochondrial function and is involved in the production of energy in the brain. The beta-subunit of MTND2P28 is involved in the transfer of electrons from the mitochondria to the cytoplasm.

Research has shown that MTND2P28 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The alpha-subunit of MTND2P28 has been shown to be overexpressed in the brains of individuals with these disorders, and the beta-subunit has been shown to play a role in the progression of neurodegeneration.

MTND2P28 has also been shown to be involved in the development of other neurodegenerative diseases, including ALS, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). The alpha-subunit of MTND2P28 has been shown to be overexpressed in the brains of individuals with ALS and has been shown to contribute to the development and progression of this disease.

In addition to its involvement in neurodegenerative diseases, MTND2P28 has also been shown to be involved in the development of certain neuropsychiatric diseases, including depression and anxiety. The beta-subunit of MTND2P28 has been shown to be involved in the regulation of brain chemistry, including the levels of neurotransmitters such as dopamine and serotonin.

Given the involvement of MTND2P28 in the development and progression of neurodegenerative diseases, as well as its potential role in the regulation of brain chemistry, MTND2P28 is a promising drug target. Researchers are currently working to develop compounds that can inhibit the activity of the alpha-subunit of MTND2P28 and prevent the development of neurodegenerative diseases.

In addition to its potential as a drug target, MTND2P28 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The alpha-subunit of MTND2P28 has been shown to be decreased in the brains of individuals with neurodegenerative diseases, and may be a useful biomarker for the diagnosis and monitoring of these conditions.

While further research is needed to fully understand the role of MTND2P28 in the development and progression of neurodegenerative diseases, the potential of this protein as a drug target and biomarker is an exciting area of research. Further studies are needed to determine the full potential of MTND2P28 as a drug target and biomarker for the prevention and treatment of neurodegenerative diseases.

Protein Name: MT-ND2 Pseudogene 28

The "MTND2P28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTND2P28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets